The Journal of Rheumatology

VOLUME 42: NO. 12                                                                                                                               DECEMBER 2015

Editorials
Can Methotrexate Prevent Knee Arthroplasties in Patients with Rheumatoid Arthritis? J.M. Kremer 2217
The Difficult Task of Assessing Psoriatic Arthritis A. Caull, M. Piga 2219

Articles
A Study of Multiple Causes of Death in RA F.A. Pinheiro, D.C. Souza, E.L. Sato 2221
The Risk of TB in Patients with RA Treated with TNF-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies J.W. Ai, S. Zhang, Q.L. Ruan, et al 2229
Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with RA in Remission: A CORRONA and NinJa Collaborative Cohort Study K. Yoshida, H. Radner, M.D. Mjaavatten, et al 2238
RA: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden A.B. Pedersen, A. Mor, F. Mehnert, R.W. Thomsen, S.P. Johnsen, M. Nørgaard 2247
Concomitant MTX Protects Against TKA in Patients with RA Treated with TNF Inhibitors S. Asai, N. Takahashi, K. Funahashi, et al 2255
Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in RA: A Systematic Review and Metaanalysis C. Vidal, T. Barnetche, J. Morel, B. Combe, C. Daïen 2261
Clinical and Radiographic Outcomes in Patients Diagnosed with Early RA in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study G. Haugeberg, P. Bayesen, K. Helgetveit, A. Prøven 2279
A Multicenter Study of Invasive Fungal Infections in Patients with Childhood-onset SLE M.F. Silva, M.P. Ferriani, M.T. Terreri, et al 2296
Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset SLE Y. Yang, S. Kumar, L.S. Lim, E.D. Silverman, D.M. Levy 2304
Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort L. Sáez-Comet, C.P. Simeon-Aznar, M. Pérez-Conesa, et al, and the RESCLE Investigators 2327
Patient’s Global Assessment as an Outcome Measure for PsA in Clinical Practice: A Surrogate for Measuring Low Disease Activity? E. Lubrano, F.M. Perrotta, W.J. Parsons, A. Marchesoni 2332
Fatigue in Ankylosing Spondylitis and Nonradiographic AxSpA: Analysis from a Longitudinal Observation Cohort M. Bedaiwi, I. Sari, A. Thavaneswaran, R. Ayearst, N. Haroon, R.D. Inman 2354
Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in AxSpA M. Dougados, E. Wood, L. Gossec, A. Dubanchet, I. Logeart, D. van der Heijde 2361
Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls S. van Genderen, A. Boonen, D. van der Heijde, et al 2369
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the USA K. Raimundo, A.M. Farr, G. Kim, G. Duna 2383

Free online via JRheum Full Release option

Contents continued on page xx

PRINTED IN CANADA – ISSN 0315-162X
Downloaded on August 4, 2021 from www.jrheum.org